Medipost Co., Ltd. is a stem cell biotechnology company based in Korea. The company focuses on developing products to address unmet medical needs. Medipost operates through four segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division collects and stores stem cells from newborns' umbilical cords. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics. Medipost's mission is to help patients with incurable diseases and address unmet medical needs through stem cells and regenerative medicine. Since its foundation in 2000, Medipost has been a leader in the global stem cell therapeutics field. They have developed the world's first regulatory-approved allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cell (hUCB-MSC) product called CARTISTEM® for patients with knee Osteoarthritis (OA). Medipost has received over 33 public R&D grants for the commercialization of stem cell therapeutics. They are committed to overcoming the boundaries of currently incurable diseases and unmet medical needs through their research and development efforts in stem cell technology and commercialization.
Headquarters
21 Daewangpangyo-Ro 644Beon-Gil, Bundang-Gu
Seongnam; Gyeonggi;
Postal Code: 463-400
Contact Details: Purchase the Madipost Co.,Ltd. report to view the information.
Website: http://www.medi-post.co.kr
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service